ORGO Stock Analysis: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$2.27
-0.13 (-5.42%)
▼
5d:
-8.47%
30d:
-8.1%
90d:
-4.62%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ORGO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ORGO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $2.27, which is considered fair relative to its 30-day fair value range of $2.36 to $2.47. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.2) compared to its historical average (18.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ORGO is in a downtrend. The price is currently testing key support at $2.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: ORGO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+32.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ORGO is in a downtrend. The price is currently testing key support at $2.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: ORGO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+32.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.36 -
$2.47
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 32.2% below Wall St target ($3.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: 5-day price weakness (-8.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.36 -
$2.47
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.24
Resistance Level
$2.59
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.25
Wall Street Target
$3.00
(+32.2%)
Revenue Growth (YoY)
-57.1%
Earnings Growth (YoY)
555.2%
Profit Margin
0.5%
PE vs Historical
-8.3 vs 18.1
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 12:38 AM ET
Data refreshes hourly during market hours. Next update: 1:38 AM
Data refreshes hourly during market hours. Next update: 1:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Arthur S Leibowitz
BUY
5000 shares
2026-03-09
Michael Joseph Driscoll
BUY
10000 shares
2026-03-09
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
